An Open-Label Safety and Efficacy Study of Reslizumab (CTx55700) for the Treatment of Pediatric Subjects With Eosinophilic Oesophagitis Who Completed Study Res-5-0002 [EXTENSION OF 700027517]

Trial Profile

An Open-Label Safety and Efficacy Study of Reslizumab (CTx55700) for the Treatment of Pediatric Subjects With Eosinophilic Oesophagitis Who Completed Study Res-5-0002 [EXTENSION OF 700027517]

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Mar 2017

At a glance

  • Drugs Reslizumab (Primary)
  • Indications Eosinophilic oesophagitis
  • Focus Adverse reactions; Registrational
  • Sponsors Ception Therapeutics
  • Most Recent Events

    • 12 Apr 2014 New trial record
    • 09 Apr 2012
    • 02 Feb 2010
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top